SCHEMBL25346325

SCHEMBL25346325

COC(=O)c1cc(=O)[nH]c(=O)n1COCC[Si](C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.35
ALDH1A1 P00352 4/20 0.35
KMT2A Q03164 3/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 5/20 0.34
MEN1 O00255 2/20 0.34
F11 P03951 1/20 0.34
KLKB1 P03952 1/20 0.33
DUT P33316 1/20 0.33
PDE2A O00408 2/20 0.33
PDE3B Q13370 2/20 0.33
PDE3A Q14432 2/20 0.33
P2RY12 Q9H244 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726956 0.88 NPC1 (0.38) NPC1ALDH1A1KMT2AKDM4EMAPT
SCHEMBL6726798 0.87 NPC1 (0.40) NPC1ALDH1A1KMT2AGAAKDM4E
SCHEMBL25346960 0.86 NPC1 (0.47) NPC1ALDH1A1KMT2AGAAKDM4E
SCHEMBL6722438 0.79 ATM (0.38) NPC1ALDH1A1KMT2AGAAKDM4E
SCHEMBL25344725 0.78 NPC1 (0.38) NPC1ALDH1A1KMT2AKDM4EHTT
SCHEMBL6723774 0.78 NPC1 (0.37) NPC1CYP1A2ALDH1A1KMT2AKDM4E
SCHEMBL6727003 0.76 NPC1 (0.37) NPC1CYP1A2ALDH1A1KMT2AKDM4E
SCHEMBL25346003 0.75 NPC1 (0.36) NPC1ALDH1A1KMT2AKDM4EHPGD
SCHEMBL6719796 0.74 DUT (0.37) NPC1ALDH1A1KMT2AKDM4EMAPT
SCHEMBL25345207 0.74 NPC1 (0.35) NPC1ALDH1A1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658262-A1 BICYCLIC IMIDE COMPOUNDS AS TRPA1 INHIBITORS D.E. Shaw Research, LLC (US) 2025-12-10 EP disclosed
US-20250136587-A1 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D. E. SHAW RESEARCH, LLC 2025-05-01 US disclosed
EP-4472627-A2 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D.E. Shaw Research, LLC (US) 2024-12-11 EP disclosed
CN-118922185-A N3-substituted uracil compounds as TRPA1 inhibitors D·E·萧尔研究有限责任公司 2024-11-08 CN disclosed
WO-2024163333-A1 BICYCLIC IMIDE COMPOUNDS AS TRPA1 INHIBITORS D. E. SHAW RESEARCH, LLC (US) 2024-08-08 WO disclosed
WO-2023150592-A2 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D.E. SHAW RESEARCH, LLC (US) 2023-08-10 WO disclosed
WO-2023150592-A2 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D.E. SHAW RESEARCH, LLC (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136587-A1 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS TRPA1, TRPV1, SLC28A1 NPC1 465/4885CYP1A2 2013/4885ALDH1A1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.